Author:
Gurion Ronit,Rozovski Uri,Itchaki Gilad,Gafter-Gvili Anat,Leibovitch Chiya,Raanani Pia,Ben-Zvi Haim,Szwarcwort Moran,Taylor-Abigadol Mor,Dann Eldad J.,Horesh Nurit,Inbar Tsofia,Tzoran Inna,Lavi Noa,Fineman Riva,Ringelstein-Harlev Shimrit,Horowitz Netanel A.
Abstract
Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies (MoAb), suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors impacting the response.
Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott©) assay in blood samples drawn from lymphoma patients 4±2 weeks after the 2nd vaccine dose. The cutoff for a positive response was set at 50AU/ml.
Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献